1. Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259–269
2. Boxer PA, Cordon JJ, Mann ME, Rodolosi LC, Vartanian MG, Rock DM, Taylor CP, Marcoux FW (1990) Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. Stroke 21(11 Suppl):III47–III51
3. Lakics V, Molnar P, Erdo SL (1995) Protection against veratridine toxicity in rat cortical cultures: relationship to sodium channel blockade. Neuroreport 7(1):89–92
4. Fern R, Ransom BR, Stys PK, Waxman SG (1993) Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam. J Pharmacol Exp Ther 266(3):1549–1555
5. Lo AC, Saab CY, Black JA, Waxman SG (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90(5):3566–3571